Procter & Gamble Health Limited (BOM:500126)
India
· Delayed Price · Currency is INR | Market Cap | 86.74B |
| Revenue (ttm) | 11.60B |
| Net Income (ttm) | 2.37B |
| Shares Out | 16.60M |
| EPS (ttm) | 142.44 |
| PE Ratio | 36.69 |
| Forward PE | n/a |
| Dividend | 160.00 (3.05%) |
| Ex-Dividend Date | Feb 21, 2025 |
| Volume | 160 |
| Average Volume | 398 |
| Open | 5,220.45 |
| Previous Close | 5,223.15 |
| Day's Range | 5,202.15 - 5,260.00 |
| 52-Week Range | 4,640.30 - 5,835.95 |
| Beta | 0.46 |
| RSI | 49.90 |
| Earnings Date | May 29, 2025 |
About Procter & Gamble Health
Procter & Gamble Health Limited engages in the manufacture and marketing of pharmaceuticals and chemical products in India and internationally. The company provides over-the-counter products, vitamins, minerals, and supplements. It offers its products under the Polybion, Cosome, Evion, Neurobion, Nasivion, Livogen, and Seven Seas brands. The company was formerly known as Merck Limited and changed its name to Procter & Gamble Health Limited in May 2019. The company was incorporated in 1967 and is headquartered in Mumbai, India. Procter & Gamble ... [Read more]
Financial Performance
In 2024, Procter & Gamble Health's revenue was 11.51 billion, a decrease of -6.37% compared to the previous year's 12.30 billion. Earnings were 2.01 billion, a decrease of -12.42%.
Financial StatementsNews
P&G Health Q2 FY25: Revenue rises 2.8% YoY to Rs 313.41 crore, net profit surges 25.6% to Rs 82.33 crore
Procter & Gamble Health Limited has reported its unaudited financial results for the quarter ended September 30, 2024, showing steady revenue growth and a notable increase in profitability. For Q2 FY2...
Procter & Gamble Health Q2 FY25 results: Stock jumps 2% ahead of result announcement
Procter & Gamble Health shares have experienced a notable increase, jumping more than 2% ahead of Q2 FY25 results. The stock opened at Rs 5,367.70, reaching a high of Rs 5,380.00 during trading hours,...